Macrogenics INC

MacroGenics reports positive interim Phase 1 results for MGC026, an antibody-drug conjugate, with enrollment advancing in multiple cancer types.

MacroGenics, Inc. announced the resignation of Dr. Karen Ferrante from its Board of Directors, effective September 1, 2026, due to personal reasons.

MacroGenics has completed the sale of its GMP manufacturing operations and CDMO business to Bora Pharmaceuticals for $122.5 million, aiming to streamline operations and focus on its core biopharmaceutical development.

MacroGenics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, where all director nominees were elected and key proposals, including auditor ratification and equity plan amendments, received stockholder approval.

MacroGenics announced first quarter 2026 financial results, highlighting a strategic divestiture of manufacturing operations and expanded ZYNYZ royalty monetization, extending cash runway through 2028.

MacroGenics announced the sale of its GMP manufacturing operations to Bora Pharmaceuticals for $122.5 million upfront, aiming to streamline its focus on pipeline advancement.

MacroGenics reports a 58% revenue increase in Q1 2026 driven by contract manufacturing and royalty revenue, alongside a 12% decrease in R&D expenses.

MacroGenics reported a net income of $16.8 million for Q3 2025, a significant decrease from $56.3 million in Q3 2024, primarily due to milestone timing and the sale of MARGENZA rights, while extending its cash runway into late 2027.

MacroGenics reported a reduced net loss and increased collaboration revenue in Q2 2025, extending its financial runway through the first half of 2027.

MacroGenics' Q1 2025 financial results show increased revenue driven by collaborative agreements and contract manufacturing, despite a net loss.

MacroGenics' Q3 2024 results show a significant revenue increase due to a $100 million milestone payment from Incyte, alongside the announcement of the sale of MARGENZA to TerSera.

MacroGenics' second quarter 2024 results show a decrease in revenue compared to the same period last year, primarily due to reduced collaboration revenue, while research and development expenses increased.

MacroGenics' 2024 10-K filing details financial results, pipeline advancements, and a strategic shift including the sale of MARGENZA.

MacroGenics, a biopharmaceutical company, released its 2023 financial results and provided updates on its oncology pipeline, including progress on vobramitamab duocarmazine and lorigerlimab.

Ezio Bonvini, Sr VP, Research & CSO of Macrogenics Inc, reported multiple transactions in common stock on August 17, 2026.

Federica F. O'Brien, a Director at Macrogenics Inc., reported transactions involving common stock, restricted stock units, and stock options.

Macrogenics Inc. reports director Scott Jackson's transactions involving restricted stock units and stock options.

Macrogenics Director William K. Heiden reported transactions involving restricted stock units and stock options.

Jay Philip Siegel, a Director at Macrogenics Inc., reported a transaction involving 3,750 shares of common stock on May 18, 2026.

Director Margaret Liu reported a transaction involving Macrogenics Inc. common stock, acquiring 3,750 shares through vested Restricted Stock Units.

MacroGenics, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for May 19th, to elect directors and vote on an amendment to increase its 2023 Equity Incentive Plan shares.

Macrogenics, Inc. has filed a definitive proxy statement with the SEC.

MacroGenics is asking stockholders to approve an amendment to its 2023 Equity Incentive Plan to increase the number of shares available for issuance by 1,250,000.

Macrogenics, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) regarding its upcoming shareholder meeting.

MacroGenics is asking stockholders to approve an amendment to its 2023 Equity Incentive Plan to increase the number of shares available for issuance by 2,000,000.

Armistice Capital, LLC, along with its managing member Steven Boyd, has reported beneficial ownership of 7.88% of MacroGenics, Inc. common stock as of June 30, 2026.

Bank of America Corporation has disclosed a beneficial ownership of 4.0% in MacroGenics Inc., holding 2,556,475 shares.

Millennium Management LLC, along with affiliated entities and Israel A. Englander, has reported beneficial ownership of 3.7% of MacroGenics, Inc. common stock as of June 30, 2026.

Millennium Management LLC and Israel A. Englander have reported a 5.4% beneficial ownership stake in MacroGenics, Inc. via a Schedule 13G filing.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 6,012,000 shares, representing 9.46% of MacroGenics, Inc.'s common stock.

Millennium Management LLC and Israel A. Englander have filed a Schedule 13G disclosing a reduction in their beneficial ownership of MacroGenics, Inc. to below the 5% threshold.